Phase 3 Multiple sclerosis trials recruiting now

All Multiple sclerosis trials, every phase

Other phases for Multiple sclerosis

Phase 3 Multiple sclerosis trials

• A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
  NCT07189325 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 1 location
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
  NCT07067463 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 63 locations
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
  NCT07299019 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 44 locations
• A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
  NCT07321093 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
  NCT05906992 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 256 locations
• An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
  NCT06675955 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
  NCT04047628 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 23 locations
• Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
  NCT05961644 · Phase: Phase 2, Phase 3 · Ages: 30 Years to 65 Years · Sex: All (male and female) · 1 location
• Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
  NCT06136728 · Phase: Phase 3 · Ages: 25 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · 129 locations
• Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
  NCT05999604 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
  NCT04302870 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 40 locations
• Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
  NCT05834855 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
  NCT05534672 · Phase: Phase 3 · Ages: 3 Months to 50 Years · Sex: All (male and female) · 2 locations
• Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
  NCT07623668 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 4 locations
• RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
  NCT05758831 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 23 locations
• Study of COYA 302 for the Treatment of ALS
  NCT07161999 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 25 locations
• Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
  NCT07220252 · Phase: Phase 2, Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 2 locations
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 51 locations
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
  NCT06408259 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 33 locations
• Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
  NCT07403266 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female) · 2 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.